Too Many Combos? FDA Reflects On Antihypertensive Approval Standards
This article was originally published in RPM Report
Executive Summary
In an unusually long preface to the questions posed to the Cardiovascular & Renal Drugs Advisory Committee on September 9, FDA reflects on the value of the ever-expanding roster of antihypertensive combination therapies. The meeting ended with a vote against Actavis/Forest Labs’ proposed nebivolol/valsartan combo.